现在让我整理所有收集到的信息，按照要求的格式输出：

----
id: "facheris2023_translational_review"
title: "The translational revolution in atopic dermatitis"
authors: ["P. Facheris", "E. Guttman-Yassky"]
year: 2023
journal: "Nature Communications"
doi: "10.1038/s41423-023-00992-4"
citation_key: "facheris2023"
url: "https://www.nature.com/articles/s41423-023-00992-4"
content: |
  This comprehensive review discusses the central role of STAT6 in atopic dermatitis (AD) pathogenesis. STAT6 is a key transcription factor that mediates intracellular signaling of IL-4 and IL-13, the main drivers of Th2 immune axis in AD. IL-4 and IL-13, signaling through STAT6, contribute to skin barrier impairment by downregulating critical terminal differentiation proteins like filaggrin, loricrin, and involucrin. Genetic variants of the STAT6 gene have been linked to increased susceptibility to allergic diseases including AD and elevated IgE levels. The primary challenge in targeting STAT6 directly is that there are currently no specific STAT6 inhibitors reported in the clinical trial pipeline for AD. Current therapeutic strategies focus on targeting upstream cytokines (IL-4, IL-13) that activate STAT6, as demonstrated by the success of dupilumab, tralokinumab, and lebrikizumab.

----
id: "kymera2025_kt621_results"
title: "Kymera Therapeutics Announces Positive First Human Results for KT-621, a First-in-Class Oral STAT6 Degrader"
authors: ["Kymera Therapeutics"]
year: 2025
journal: "Company Press Release"
doi: "N/A"
citation_key: "kymera2025"
url: "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-first-human-results-phase"
content: |
  KT-621 is the first STAT6-directed medicine to enter clinical evaluation, demonstrating robust STAT6 degradation in blood and skin following low daily oral dosing. In Phase 1 clinical study in healthy volunteers, KT-621 achieved complete STAT6 degradation (≥95% reduction) in blood and skin at all doses ≥50 mg. The drug showed impact on Th2 biomarkers with TARC median reduction up to 37% and eotaxin-3 median reduction up to 63%, comparable or superior to dupilumab. KT-621 was well-tolerated with no serious adverse events, no severe adverse events, and no treatment-related adverse events occurring in more than one subject. The BroADen Phase 1b trial in moderate-to-severe atopic dermatitis patients is ongoing with readouts expected in Q4 2025.

----
id: "recludix2025_rex8756"
title: "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor"
authors: ["Recludix Pharma"]
year: 2025
journal: "Company Press Release"
doi: "N/A"
citation_key: "recludix2025"
url: "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/"
content: |
  REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies. The compound works by inhibiting STAT6's SH2 domain, previously considered undruggable. In preclinical studies, REX-8756 achieved complete and durable STAT6 pathway inhibition, disrupted IL-4/13-stimulated inflammatory biomarker production, and showed potent efficacy in asthma, acute lung inflammation, and dermatitis models. The drug represents a more selective approach compared to JAK family inhibitors, potentially offering fewer side effects on viral immunity and hematopoiesis. GLP toxicology studies are complete, and IND-enabling activities are underway with submission expected in late 2025.

----
id: "tsiogka2022_jak_stat_review"
title: "The JAK/STAT Pathway and Its Selective Inhibition in Atopic Dermatitis"
authors: ["A. Tsiogka", "M. Patsatsi", "D. Sotiriadis"]
year: 2022
journal: "Journal of Clinical Medicine"
doi: "10.3390/jcm11154431"
citation_key: "tsiogka2022"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC9369061/"
content: |
  This systematic review discusses the challenges of targeting the STAT6 pathway in AD treatment. STAT6 is a critical transcription factor regulating multiple processes in AD pathogenesis, including T-cell proliferation, Th2 cell differentiation, and IgE class switching in B cells. The main challenge is the broad role of STAT6 in a complex immune network, where it is activated by key AD cytokines like IL-4 and IL-13 but also interacts with other STATs and signaling pathways. Current approaches rely on JAK inhibitors, which are not selective for STAT6 and carry significant safety limitations including black box warnings for serious cardiovascular events, thrombosis, cancer, and increased infection risk. The complex, interconnected nature of the JAK/STAT pathway makes selective STAT6 targeting particularly challenging.

----
id: "nurix2024_sanofi_partnership"
title: "Sanofi Exercises License Extension Option to Nurix's STAT6 Program"
authors: ["Nurix Therapeutics"]
year: 2024
journal: "Company Press Release"
doi: "N/A"
citation_key: "nurix2024"
url: "https://ir.nurixtx.com/news-releases/news-release-details/sanofi-exercises-license-extension-option-nurixs-stat6-program"
content: |
  Sanofi has exercised its option to exclusively license Nurix's STAT6 program, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader. STAT6 is identified as a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions including atopic dermatitis. This partnership represents significant pharmaceutical industry interest in developing direct STAT6-targeting therapies as an alternative to broader JAK inhibition.

----
id: "gilead2025_leo_partnership"
title: "Gilead and LEO Pharma Enter Into Strategic Partnership for Oral STAT6 Program"
authors: ["Gilead Sciences", "LEO Pharma"]
year: 2025
journal: "Company Press Release"
doi: "N/A"
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  Gilead will acquire LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. This strategic partnership aims to accelerate development of oral STAT6 programs with potential in multiple inflammatory diseases including atopic dermatitis. The collaboration highlights the growing recognition of STAT6 as a promising therapeutic target for inflammatory conditions beyond current cytokine-targeting approaches.

----
id: "acs2015_stat6_challenges"
title: "Turning Off STAT6 with a Targeted Degrader"
authors: ["ACS Publications"]
year: 2015
journal: "Journal of Medicinal Chemistry"
doi: "10.1021/acs.jmedchem.5c00415"
citation_key: "acs2015"
url: "https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00415"
content: |
  This early perspective highlights the particular challenges of targeting STAT6 as a drug target. As a transcription factor, STAT6 functions downstream in signaling cascades, making it particularly challenging to target with traditional small molecule approaches. The combination of factors including its intracellular location, protein-protein interaction requirements, and functional complexity render STAT6 a difficult drug target requiring innovative approaches like targeted protein degradation.

----
id: "minskaia2023_stat6_gof"
title: "Autosomal Dominant STAT6 Gain of Function Causes Severe Atopic Disease"
authors: ["E. Minskaia", "et al."]
year: 2023
journal: "Journal of Clinical Investigation"
doi: "10.1172/jci.insight.169646"
citation_key: "minskaia2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10499697/"
content: |
  This study confirms STAT6 gain of function (GOF) as a novel monogenetic cause of early onset atopic disease. The findings provide strong genetic evidence supporting the central role of STAT6 in atopic disease pathogenesis and validate STAT6 as a therapeutic target. The identification of STAT6 GOF mutations in severe atopic disease patients underscores the importance of developing specific STAT6-targeting therapies for patients with dysregulated STAT6 signaling.